TVRD

Tvardi Therapeutics, Inc.

TVRD, USA

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

https://tvarditherapeutics.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TVRD
stock
TVRD

Behavioral Patterns of TVRD and Institutional Flows Stock Traders Daily

Read more →
TVRD
stock
TVRD

Tvardi Therapeutics updates STAT3 fibrosis-focused clinical pipeline TipRanks

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

$

Analyst Picks

Strong Buy

4

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Low

1.59

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-19.83 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-14.16 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.40

Low 1

High 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Tvardi Therapeutics, Inc.

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.57

Latest Release

Date

2025-09-30

EPS Actual

-0.59

EPS Estimate

-0.96

EPS Difference

0.37

Surprise Percent

38.5417%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.